Tantangan Tata Laksana Psoriasis Vulgaris Sedang hingga Berat dengan Terapi Sistemik Konvensional

Oleh :

dr. Fresa Nathania Rahardjo, M.Biomed, Sp.KK

Terapi sistemik konvensional yang umum diberikan untuk psoriasis vulgaris derajat sedang hingga berat adalah metotreksat dan siklosporin. Namun, ada kemungkinan penghentian pengobatan karena efek samping yang lebih tinggi dibandingkan pada agen biologik. Agen biologik dapat menjadi opsi bagi pasien yang mengalami efek samping bermakna atau yang sudah tidak memberikan respons terhadap terapi konvensional.[1,4]

Psoriasis merupakan penyakit inflamasi kronis yang diderita seumur hidup oleh pasien. Oleh karena itu, kepuasan pasien terhadap terapi jangka panjang perlu diperhatikan. Permasalahan yang saat ini perlu diatasi adalah cukup tinggi nya proporsi pasien psoriasis sedang hingga berat yang tidak puas terhadap terapi sistemik konvensional.[1,4]

Sekilas tentang Klasifikasi Derajat Keparahan Psoriasis

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013 Jan;68(1):64-72.
2. Saurat JH, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.
3. Barker J, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate to severe plaque psoriasis: results of an open label, active controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165:1109-1117.
4. Christophers E, et al. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat. 2012;24(3):193-198.
5. Norlin JM, et al. Real-world outcomes in 2646 psoriasis patients: one in five has PASI >10 and/or DLQI < 10 under ongoing systemic therapy. J Dermatolog Treat. 2017;28(6):500-504.
6. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii65-ii73.
7. Novianto E, Meisyah E, Budianti WK. Alur Tatalaksana Psoriasis Vulgaris di Indonesia. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia. 2019;1-13.
8. Drovaroka V, Markham T. Psoriasis: current treatment option and recent advances. Drug Review. 2013;4:13-18.
9. Boca A, Petrescu B, Buzoainu A. Current therapeutic options in psoriasis. HVM Bioflux. 2014;6(1):6-10.
10. Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014 Apr 24;144:w13968.
11. Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020 Oct;183(4):628-637.
12. Gisondi P, Bellinato F, Bruni M, et al. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol Ther. 2020 Nov;33(6):e14281.
13. Ohtsuki M, Morita A, Igarashi A, et al. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. J Dermatol. 2017;44(10):1105-1111.
14. Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci. 2020 Mar 1;21(5):1690.
15. Carretero G, Ferrandiz C, Dauden E, et al; BIOBADADERM Study Group. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):156-63.